Trial Profile
Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled Phase III Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Borneol/edaravone (Primary) ; Edaravone
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms TASTE
- Sponsors Jiangsu Simcere Pharmaceutical
- 24 Mar 2022 According to a Simcere Pharmaceutical Group media release, the data from this trial was published on February 16, 2021 in STROKE, a leading international authoritative medicine journal.
- 29 Sep 2021 Results of sub-group analysis presented at the Hypertension Scientific Session 2021.
- 12 Jan 2017 Status changed from active, no longer recruiting to completed.